A study found that a patient's optimism can influence clinicians' survival predictions, leading to overestimation of time remaining. This bias may hinder timely end-of-life care decisions.
A Mayo Clinic study found that extended chemotherapy, a normal CA 19-9 tumor marker, and a dead tumor after surgery can significantly increase survival time for patients with advanced pancreatic cancer. The study achieved an average survival time of 58.8 months, or nearly five years.
A retrospective cohort study found that surgery was associated with a 44% increased chance of survival for women with HER2+ stage 4 breast cancer, especially those with Medicare or private insurance. The study also revealed disparities in healthcare access and outcomes due to race and socioeconomic factors.
Researchers found that chronic morphine treatment decreased survival in control mice, but not in sickle mice with sickle cell disease. Chronic opioid therapy also caused hyperalgesia, a condition of increased pain sensitivity, in sickle mice. The study suggests that opioids may still be effective for managing pain in SCD patients despi...
A study published in JAMA reveals significant improvement in the survival rate of extremely preterm babies in Sweden, rising from 70% to 77%, while complications decreased, between 2014-2016 and 2004-2007.
The NRG Oncology trial suggests adding docetaxel-based chemotherapy to standard treatment should be considered for men with high-risk prostate cancer. The study found improved overall survival, disease-free survival, and reduced rates of distant metastases.
A Children's Oncology Group study shows that postoperative radiation improves outcomes for children with ependymoma, achieving seven-year progression-free survival for over 75% of patients and overall survival for 85%. The findings provide evidence that radiation can improve outcomes despite age and tumor subtype.
A large UK study found that heart failure survival rates have only improved modestly since 2000, with significant disparities in outcomes across different socioeconomic groups. The research highlights the need for increased investment in heart failure services to address these inequalities.
MIT researchers have developed a new toxicity test that can measure chemical effects on cell survival with greater sensitivity than popular tests. The MicroColonyChip system uses tiny wells to form small colonies, allowing for rapid results in just a few days.
A nationwide cohort study found that timely kidney transplant significantly increases survival in patients with lupus nephritis and end-stage renal disease. The study revealed a 70% reduction in overall risk of death, with benefits observed across various subgroups, including African Americans, Hispanics, Asians, and both sexes.
A state-by-state analysis reveals that melanoma survival rates differ substantially across the US, with states having more practicing physicians and higher percentage of Caucasians experiencing lower survival rates. The study highlights the need for targeted approaches to improve care and reduce deaths associated with melanoma.
A new mathematical model developed by University of Southern Denmark researcher Fernando Colchero can help predict the population growth of endangered species. The model takes into account age-specific survival and reproduction rates, as well as trade-offs between these factors, resulting in more accurate predictions.
A recent study published in the Journal of Clinical Oncology found that time to biochemical failure can be used as a surrogate endpoint for locally advanced prostate cancer treatment, reducing overall survival benefit by 6% compared to traditional endpoints. The analysis of NRG-RTOG 9202 clinical trial results showed significant associ...
The MYSTIC trial found that first line immunotherapy combination with durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer. However, a subgroup of patients with high tumour mutational burden showed improved overall survival with the combination treatment.
Researchers analyzed data from over 109,000 out-of-hospital cardiac arrests and found that states with required CPR education had higher bystander CPR rates and improved survival outcomes. Neurologically favorable survival was also more common in these states.
A study found that men with prostate cancer value quality of life and will trade off survival odds for fewer side effects, including urinary incontinence and impotence. The research suggests that patients may prefer less invasive treatments like focal therapy or active surveillance to reduce harm.
Researchers found that targeting tumor sites with radiation or surgery after initial treatment can significantly improve overall survival time for patients. Progression-free survival and toxicity data also showed benefits, with median overall survival times of up to 41.2 months.
Pediatric kidney transplant recipients face worsening long-term survival disparities, despite overall improvement in patient survival from 1995 to 2014. Racial/ethnic differences persist, with Black children at highest risk of death compared to White and Hispanic counterparts.
A large comparison study found that radiotherapy to the prostate improved failure-free survival but not overall survival in men with newly diagnosed metastatic prostate cancer and a low burden of disease. The treatment was well-tolerated, with only modest side effects.
Atezolizumab, an antibody targeting PD-L1, improved survival in metastatic triple negative breast cancer patients by 20%, particularly those with PD-L1 positive tumors. The combination therapy also reduced disease worsening and death risk by 38% in PD-L1 positive subgroup
The PALOMA-3 study found that the CDK4/6 inhibitor palbociclib significantly improves progression-free survival in patients with HR+/HER2- advanced breast cancer. In a new analysis, palbociclib plus fulvestrant was shown to improve overall survival by 6.9 months compared to placebo plus fulvestrant.
Researchers at USC and the Los Angeles Cancer Surveillance Program found that 15- to 39-year-olds have the best survival rate among any age group for many years. The analysis adjusted for Kaposi's sarcoma and lymphomas, which were linked to the HIV/AIDS epidemic in the US.
Patients with metastatic non-small cell lung cancer (NSCLC) treated at academic centers had higher 2-year survival rates than those treated at community-based centers. The study found significant differences in survival outcomes based on facility type, histology, and molecular profile.
A new study reveals that giraffe babies pass on their unique spot patterns to their mothers, with larger spots and irregular shapes linked to increased survival. Researchers used modern imaging techniques to analyze coat patterns in wild Masai giraffes, confirming a 49-year-old hypothesis about heritability.
A McMaster University-led review of 52 articles found no significant association between progression-free survival and health-related quality of life in cancer patients. The study suggests that clinical trials should measure health-related quality of life directly to ensure patients are receiving effective treatments.
A recent SWOG study found that women diagnosed with non-small cell lung cancer (NSCLC) have a higher overall survival rate compared to men. The analysis revealed significant differences in survival rates among female and male patients, regardless of their smoking history or other factors.
A new study examines the link between socioeconomic status and racial & ethnic disparities in childhood cancer survival. The research found that socioeconomic status significantly mediate the association between race/ethnicity and survival for certain types of childhood cancers, such as acute lymphoblastic leukemia, acute myeloid leuke...
A large-scale retrospective study has shown that nearly doubling the number of lymph nodes removed during operations for right-sided colon cancers improves the survival rate for these patients. The study found improved outcomes when at least 22 lymph nodes were harvested, with a 20% increase in five-year survival rates.
Checkpoint inhibitors have been shown to double median survival and more than double four-year survival rates for patients with melanoma brain metastases. The study analyzed data from over 1,500 cancer programs, revealing a significant improvement in overall survival.
A study by NRG Oncology/RTOG 0424 found that MGMT promoter methylation is associated with improved progression-free and overall survival in high-risk, low-grade glioma patients. The analysis suggests that MGMT promoter methylation should be incorporated into future clinical trial designs to risk-stratify LGG patients.
The ADMYRE trial found a statistically significant increase in overall survival with plitidepsin plus dexamethasone compared to dexamethasone alone. The two-stage model showed a 11.6-month overall survival in the plitidepsin arm, exceeding 6.4 months for dexamethasone.
Researchers at UCLA have developed a personalized glioblastoma vaccine that shows promise in increasing long-term survival. The vaccine, known as DCVax-L, has been shown to extend median survival time from 15-17 months to 23.1 months.
A new trial presented at ASCO18 shows that PET scans can improve treatment outcomes for esophageal cancer patients. Patients who responded to induction chemotherapy had a median overall survival of 46 months, while those who did not respond had a 27-month median survival, significantly better than previous studies.
The study found that matching targeted therapies to tumor-specific gene mutations improved progression-free and overall survival in patients with advanced disease. Receiving matched targeted therapy was also an independent factor for predicting longer overall survival.
According to a new analysis of over 8,000 patients, African-American men with advanced prostate cancer who received docetaxel-based therapies had a lower risk of death than white men. This finding is significant, as it challenges the long-held notion that racial disparities in prostate cancer survival are due to biological differences.
A lower-fat diet was linked to increased breast cancer overall survival among postmenopausal women, although the increase may be partly due to better survival from other causes. The study found modest increases in vegetable, fruit, and grain intake in the lower-fat group.
Researchers studied the effects of El Niño and Pacific decadal oscillation (PDO) on Nazca booby survival. Young birds face low survival rates during El Niño events due to depleted fish stocks, while adults experience higher mortality in warm PDO phases due to increased reproduction difficulties.
Researchers found that fawn survival is higher in landscapes with mixed forest and agricultural cover, but human-caused mortalities are greater. The study suggests that efforts to alter fawn survival may be challenging due to predation, and that reducing antlerless harvests may be more effective.
A study by Yale researchers found significant disparities in lung cancer care and survival between the US and England. In the US, 25% of patients were diagnosed at stage 1, compared to 15% in England, while 45% of US patients were diagnosed late-stage, versus 52% in England.
The SORAMIC study found no overall survival benefit of adding selective internal radiation therapy (SIRT) to sorafenib for patients with unresectable primary liver cancer. However, subgroup analyses suggested possible survival benefits in younger patients and those with certain cirrhosis characteristics.
The POPLAR trial found that atezolizumab significantly improved overall survival compared to docetaxel in previously treated advanced non-small-cell lung cancer patients. Long-term overall survival benefits were observed across histology and PD-L1 expression levels.
A recent NRG Oncology study found that high-dose radiotherapy improves biochemical control and reduces distant metastases in men with intermediate-risk prostate cancer, but does not enhance overall survival. The treatment also resulted in more side effects compared to standard radiotherapy.
Immunotherapy has shown promising results in treating metastatic breast cancer, with a median progression-free survival of 33 months and median overall survival of 82 months. The treatment has been found to improve PFS and OS in both luminal and non-luminal subtypes, offering new hope for patients with this incurable disease.
A new study by NYU Langone Health reveals that patients from lower-income areas have a significantly reduced chance of surviving anal cancer. The research, led by Dr. Daniel Becker, found a strong association between median household income and overall survival rates.
A study published in The BMJ found little evidence that national cancer policy initiatives since 2000 have improved short-term cancer survival in England. Despite steady improvements in overall cancer survival, socioeconomic inequalities in survival remain a major public health problem.
A study published in CANCER found that living in low-income areas increases the risk of early death among patients with anal cancer. The researchers analyzed data from 9,550 patients and found that those in lower income areas had worse overall survival and cancer-specific survival compared to those in higher income areas.
Research reveals geographical differences in lung cancer treatment rates in England significantly impact patient survival. If optimal treatment levels were achieved, approximately 800 additional years of life could be gained annually for patients.
A study found that patients undergoing elective total hip arthroplasty (THA) have a slightly improved survival rate compared to the general population. After ten years, higher survival rates were observed among THA patients, particularly those with primary osteoarthritis.
The CONCORD-3 study reveals global improvement in cancer survival, with some countries experiencing significant gains, while others lag behind. However, disparities in childhood cancers and incomplete data in Africa limit the accuracy of these findings.
Survival rates for in-hospital cardiac arrests have improved over the past 15 years, with a significant increase in both on-hours and off-hours groups. However, patients who experience cardiac arrest during nights or weekends continue to face lower survival rates compared to those who arrest during daytime hours.
A recent study by USC researchers found that survival among adolescents and young adults with cancer has not improved over the past three decades. The study breaks down cancer survival rates by race, ethnicity, age group, socioeconomic status, and cancer stage, highlighting disparities in health outcomes.
Patients with glioblastoma who received TTFields therapy plus chemotherapy had better overall survival and progression-free survival compared to those receiving chemotherapy alone. The study showed significant improvement in treatment outcomes for this aggressive brain tumor.
A new study found that inherited variation in the ADAMTSL1 gene is associated with a poorer survival rate in early-onset breast cancer patients. The research, published in Nature Communications, suggests that this genetic factor may be used to improve prognostic models and inform treatment decisions.
Large racial disparities were found in the survival of patients with ovarian, colon, and breast cancers in the United States. Black women had consistently worse survival compared to white women, despite similar stage distributions. The five-year net survival for black women was lower than for white women in all three types of cancer.
A subset analysis of the FLAURA trial found that osimertinib improved progression-free survival by 16.5 months compared to 11.0 months with standard therapy in Asian patients with EGFR-mutated non-small-cell lung cancer, resulting in a hazard ratio of 0.54.
A new study published in Gastroenterology found that health insurance coverage differences account for nearly half of the black-white survival disparity in colorectal cancer patients. The study analyzed data from 199,098 CRC patients aged 18-64 and found a significant impact of insurance status on treatment outcomes.
Researchers identified four genes - KRAS, CDKN2A, SMAD4, and TP53 - that influence pancreatic cancer survival. Patients with three or four altered genes had poorer disease-free and overall survival rates compared to those with single or dual alterations.
Researchers at Ohio State University Wexner Medical Center have discovered a DNA-level biomarker that can predict overall survival for patients with anaplastic astrocytoma, a rare form of brain cancer. The study found that MGMT promoter methylation status is significantly associated with overall survival outcomes.
A phase III trial demonstrates a 32 percent overall survival rate at five years, setting a new benchmark for patients with inoperable stage III NSCLC. The trial also confirms that using a higher radiation dose is not beneficial and can lead to detrimental outcomes.
Researchers found that children with Medicaid and private insurance had similar survival rates, but those without insurance were at a higher risk of death. The study suggests that Medicaid is comparable to private insurance for kids with cancer.